drugset / Trial / NCT01289132
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azilsartan | Unknown | 5 mg | Oral |
| Subject | Azilsartan | Unknown | 10 mg | Oral |
| Subject | Azilsartan | Unknown | 20 mg | Oral |
| Subject | Azilsartan | Unknown | 40 mg | Oral |
| Subject | Azilsartan | Unknown | 80 mg | Oral |
| Comparator | Candesartan cilexetil | Unknown | 12 mg | Oral |